Related Experiment Video
Updated: Dec 11, 2025
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
[Clinical Efficacy of Allo-HSCT on FLT3-ITD Positive AML Patients]
Hui Zhao1, Huan-Xu Guo1, Fang Xiao1
1Department of Hematology，Tangdu Hospital of Air Force Medical University, Xi'an 710038, Shaanxi Province, China.
Objective:
To study the clinical efficacy of allo-HSCT on FLT3-ITD positive AML patients.
Methods:
The clinical data and curative efficacy of 56 FLT3-ITD+ AML patients treated with allo-HSCT in our hospital from January 2012 to December 2018 were analyzed and evaluated.
Results:
Neutrophil implantation was successful for all the patients; The median time of granulocyte hematopoietic reconstruction and megakaryocyte hematopoietic reconstruction was 13 (10-20) d and 15 (9-23) d respectively. The median follow-up time for patients 34.3 (5.6-101.4) months, 41 patients were alive and 15 patients dead at the end of follow-up. The 3 years-OS and -DFS rate was 71.2% and 65.6%, respectively. Univariate analysis showed that the OS rate of patients without aGVDH (81.2±9.4)% was significantly higher than that of patients with aGVDH (55.4±9.1) % (χ2=5.309，P＜0.05). The OS rate of patients achieved CR after one chemotherapy course before allo-HSCT was (80.2±9.2)%, which was significantly higher than that of patients achieved CR after more chemotherapy courses (χ2=4.275，P＜0.05). Cox multivariate survival analysis showed that CR after more chemotherapy courses and aGVDH after transplantation were risk factors for OS rate.
Conclusion:
Allo-HSCT can improve the prognosis of FLT3-ITD+ AML patients. The patients achieved CR after one chemotherapy course before allo-HSCT and patients without aGVDH after allo-HSCT have a better prognosis.
